Your browser doesn't support javascript.
loading
Discovery of a chemical compound that suppresses expression of BEX2, a dormant cancer stem cell-related protein.
Saijoh, Satoshi; Nakamura-Shima, Mao; Shibuya-Takahashi, Rie; Ito, Ryo; Sugawara, Akira; Yamazaki, Tomoko; Imai, Takayuki; Asada, Yukinori; Matsuura, Kazuto; Iwai, Wataru; Wakui, Yuta; Abue, Makoto; Kawamura, Sadafumi; Katayose, Yu; Fujimori, Haruna; Mochizuki, Mai; Yasuda, Jun; Yamaguchi, Kazunori; Sugamura, Kazuo; Satoh, Kennichi; Katori, Yukio; Tamai, Keiichi.
Afiliação
  • Saijoh S; Division of Cancer Stem Cells, Miyagi Cancer Center Research Institute, 47-1, Medeshima-Shiode, Natori, Miyagi, Japan; Department of Otolaryngology-Head and Neck Surgery, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, Japan; Head and Neck Surgery, Miyagi Ca
  • Nakamura-Shima M; Division of Cancer Stem Cells, Miyagi Cancer Center Research Institute, 47-1, Medeshima-Shiode, Natori, Miyagi, Japan.
  • Shibuya-Takahashi R; Division of Cancer Stem Cells, Miyagi Cancer Center Research Institute, 47-1, Medeshima-Shiode, Natori, Miyagi, Japan.
  • Ito R; Division of Molecular Physiology and Metabolism, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, Japan.
  • Sugawara A; Department of Molecular Endocrinology, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, Japan.
  • Yamazaki T; Department of Head and Neck Medical Oncology, Miyagi Cancer Center, 47-1, Medeshima-Shiode, Natori, Miyagi, Japan.
  • Imai T; Head and Neck Surgery, Miyagi Cancer Center, 47-1, Medeshima-Shiode, Natori, Miyagi, Japan.
  • Asada Y; Head and Neck Surgery, Miyagi Cancer Center, 47-1, Medeshima-Shiode, Natori, Miyagi, Japan.
  • Matsuura K; Head and Neck Surgery, Miyagi Cancer Center, 47-1, Medeshima-Shiode, Natori, Miyagi, Japan.
  • Iwai W; Gastroenterology, Miyagi Cancer Center, 47-1, Medeshima-Shiode, Natori, Miyagi, Japan.
  • Wakui Y; Gastroenterology, Miyagi Cancer Center, 47-1, Medeshima-Shiode, Natori, Miyagi, Japan.
  • Abue M; Gastroenterology, Miyagi Cancer Center, 47-1, Medeshima-Shiode, Natori, Miyagi, Japan.
  • Kawamura S; Urology, Miyagi Cancer Center, 47-1, Medeshima-Shiode, Natori, Miyagi, Japan.
  • Katayose Y; Division of Gastroenterologic and Hepato-biliary-pancreatic Surgery, Tohoku Medical and Pharmaceutical University, 1-15-1, Fukumuro, Miyagino-ku, Sendai, Miyagi, Japan.
  • Fujimori H; Division of Cancer Stem Cells, Miyagi Cancer Center Research Institute, 47-1, Medeshima-Shiode, Natori, Miyagi, Japan.
  • Mochizuki M; Division of Cancer Stem Cells, Miyagi Cancer Center Research Institute, 47-1, Medeshima-Shiode, Natori, Miyagi, Japan.
  • Yasuda J; Molecular and Cellular Oncology, Miyagi Cancer Center Research Institute, 47-1, Medeshima-Shiode, Natori, Miyagi, Japan.
  • Yamaguchi K; Molecular and Cellular Oncology, Miyagi Cancer Center Research Institute, 47-1, Medeshima-Shiode, Natori, Miyagi, Japan.
  • Sugamura K; Molecular and Cellular Oncology, Miyagi Cancer Center Research Institute, 47-1, Medeshima-Shiode, Natori, Miyagi, Japan.
  • Satoh K; Division of Cancer Stem Cells, Miyagi Cancer Center Research Institute, 47-1, Medeshima-Shiode, Natori, Miyagi, Japan; Division of Gastroenterology, Tohoku Medical and Pharmaceutical University, 1-15-1, Fukumuro, Miyagino-ku, Sendai, Miyagi, Japan.
  • Katori Y; Department of Otolaryngology-Head and Neck Surgery, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, Japan.
  • Tamai K; Division of Cancer Stem Cells, Miyagi Cancer Center Research Institute, 47-1, Medeshima-Shiode, Natori, Miyagi, Japan. Electronic address: tamaikeiichi@med.tohoku.ac.jp.
Biochem Biophys Res Commun ; 537: 132-139, 2021 01 22.
Article em En | MEDLINE | ID: mdl-33412384
Cancer stem cells (CSCs) are believed to cause cancer metastasis and recurrence. BEX2 (brain expressed X-linked gene 2) is a CSC-related gene that is expressed in dormant CSCs in cholangiocarcinoma and induces resistance against chemotherapy. The aim of the present study was to identify small compounds that have activity to inhibit BEX2 expression and result in the attenuation of CSC-related phenotypes. We screened 9600 small chemical compounds in high-throughput screening using cholangiocarcinoma cell line HuCCT1 expressing BEX2 protein fused with NanoLuc, and identified a compound, BMPP (1, 3-Benzenediol, [4-(4-methoxyphenyl)-1H-pyrazol-3-yl]). BMPP was found to exert decreasing effects on BEX2 protein expression and G0 phase population of the tumor cells, and increasing effects on ATP levels and chemotherapeutic sensitivity of the cells. These findings indicate that BMPP is a valuable chemical compound for reducing dormant CSC-related phenotypes. Thus, the identification of BMPP as a potential CSC suppressor provides scope for the development of novel therapeutic modalities for the treatment of cancers with BEX2 overexpressing CSCs.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Células-Tronco Neoplásicas / Descoberta de Drogas / Proteínas do Tecido Nervoso / Antineoplásicos Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Biochem Biophys Res Commun Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Células-Tronco Neoplásicas / Descoberta de Drogas / Proteínas do Tecido Nervoso / Antineoplásicos Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Biochem Biophys Res Commun Ano de publicação: 2021 Tipo de documento: Article